Status:
ACTIVE_NOT_RECRUITING
Superior Vena Cava Isolation Plus Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) has limited success. The superior vena cava (SVC) has been identified as one of the most common non-pulmonary vein triggers for ...
Detailed Description
Catheter ablation has emerged as an effective treatment for drug-refractory PAF and is recommended as first-line therapy by current guidelines. PVI is considered the cornerstone of catheter ablation f...
Eligibility Criteria
Inclusion
- Symptomatic paroxysmal AF that are unresponsive to antiarrhythmic drugs (one or more than one).
- Willing to undergo catheter ablation for AF.
Exclusion
- History of any type of catheter ablation for cardiac arrhythmias.
- Sinus node dysfunction that requires permanent pacemaker implantation.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06183619
Start Date
February 1 2024
End Date
May 31 2025
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Science, Fuwai hospital
Beijing, Beijing Municipality, China, 100037